{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T09:39:50Z","timestamp":1792143590904,"version":"4.4.0"},"reference-count":131,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T00:00:00Z","timestamp":1782345600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T00:00:00Z","timestamp":1782345600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Psychiatry"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1038\/s41380-026-03722-0","type":"journal-article","created":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T17:59:07Z","timestamp":1782410347000},"page":"6532-6546","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Novel approaches in depression treatment: from rapid-acting antidepressants to personalized interventions"],"prefix":"10.1038","volume":"31","author":[{"given":"Clotilde","family":"Guidetti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Fava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George I.","family":"Papakostas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,25]]},"reference":[{"key":"3722_CR1","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/S0140-6736(15)60692-4","volume":"386","author":"Global Burden of Disease Study 2013 Collaborators","year":"2015","unstructured":"Global Burden of Disease Study 2013 Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;386:743\u2013800. https:\/\/doi.org\/10.1016\/S0140-6736(15)60692-4.","journal-title":"Lancet"},{"key":"3722_CR2","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1001\/jamapsychiatry.2017.4602","volume":"75","author":"DS Hasin","year":"2018","unstructured":"Hasin DS, Sarvet AL, Meyers JL, Saha TD, Ruan WJ, Stohl M, et al. Epidemiology of adult DSM-5 major depressive disorder and its specifiers in the United States. JAMA Psychiatry. 2018;75:336\u201346. https:\/\/doi.org\/10.1001\/jamapsychiatry.2017.4602.","journal-title":"JAMA Psychiatry"},{"key":"3722_CR3","doi-asserted-by":"publisher","unstructured":"Brody DJ, Hughes JP Depression prevalence in adolescents and adults: United States, August 2021-August 2023. NCHS Data Brief. 2025:1. https:\/\/doi.org\/10.15620\/cdc\/174579.","DOI":"10.15620\/cdc\/174579"},{"key":"3722_CR4","doi-asserted-by":"publisher","unstructured":"Elgaddal N, Weeks JD, Mykyta L Characteristics of adults age 18 and older who took prescription medication for depression: United States, 2023. NCHS Data Brief. 2025:1. https:\/\/doi.org\/10.15620\/cdc\/174589.","DOI":"10.15620\/cdc\/174589"},{"key":"3722_CR5","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/s0193-953x(05)70283-5","volume":"19","author":"M Fava","year":"1996","unstructured":"Fava M, Davidson KG. Definition and epidemiology of treatment-resistant depression. Psychiatr Clin North Am. 1996;19:179\u2013200. https:\/\/doi.org\/10.1016\/s0193-953x(05)70283-5.","journal-title":"Psychiatr Clin North Am"},{"key":"3722_CR6","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1136\/bmjebm-2019-111238","volume":"25","author":"JC Jakobsen","year":"2020","unstructured":"Jakobsen JC, Gluud C, Kirsch I. Should antidepressants be used for major depressive disorder? BMJ Evid Based Med. 2020;25:130 https:\/\/doi.org\/10.1136\/bmjebm-2019-111238.","journal-title":"BMJ Evid Based Med"},{"key":"3722_CR7","doi-asserted-by":"publisher","first-page":"18m12246","DOI":"10.4088\/JCP.18m12246","volume":"80","author":"D Misdrahi","year":"2019","unstructured":"Misdrahi D, Tessier A, Daubigney A, Meissner WG, Schurhoff F, Boyer L, et al. Prevalence of and risk factors for extrapyramidal side effects of antipsychotics: results from the national FACE-SZ cohort. J Clin Psychiatry. 2019;80:18m12246 https:\/\/doi.org\/10.4088\/JCP.18m12246.","journal-title":"J Clin Psychiatry"},{"key":"3722_CR8","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/s0006-3223(99)00230-9","volume":"47","author":"RM Berman","year":"2000","unstructured":"Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry. 2000;47:351\u20134. https:\/\/doi.org\/10.1016\/s0006-3223(99)00230-9.","journal-title":"Biol Psychiatry"},{"key":"3722_CR9","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-019-2359-1","volume":"19","author":"SY Smith-Apeldoorn","year":"2019","unstructured":"Smith-Apeldoorn SY, Veraart JKE, Kamphuis J, van Asselt ADI, Touw DJ, Aan Het Rot M, et al. Oral esketamine for treatment-resistant depression: rationale and design of a randomized controlled trial. BMC Psychiatry. 2019;19:375 https:\/\/doi.org\/10.1186\/s12888-019-2359-1. Erratum in: BMC Psychiatry. 2020 Jan 8;20(1):9. 10.1186\/s12888-019-2398-7. PMID: 31783823; PMCID: PMC6884875","journal-title":"BMC Psychiatry"},{"key":"3722_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1056\/NEJMp1903305","volume":"381","author":"J Kim","year":"2019","unstructured":"Kim J, Farchione T, Potter A, Chen Q, Temple R. Esketamine for treatment-resistant depression - first FDA-approved antidepressant in a new class. N Engl J Med. 2019;381:1\u20134. https:\/\/doi.org\/10.1056\/NEJMp1903305.","journal-title":"N Engl J Med."},{"key":"3722_CR11","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1176\/appi.ajp.2017.17040472","volume":"175","author":"ST Wilkinson","year":"2018","unstructured":"Wilkinson ST, Ballard ED, Bloch MH, Mathew SJ, Murrough JW, Feder A, et al. The Effect of a single dose of intravenous ketamine on suicidal ideation: a systematic review and individual participant data meta-analysis. Am J Psychiatry. 2018;175:150\u20138. https:\/\/doi.org\/10.1176\/appi.ajp.2017.17040472.","journal-title":"Am J Psychiatry"},{"key":"3722_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-023-05017-y","volume":"23","author":"DJ Fu","year":"2023","unstructured":"Fu DJ, Zhang Q, Shi L, Borentain S, Guo S, Mathews M, et al. Esketamine versus placebo on time to remission in major depressive disorder with acute suicidality. BMC Psychiatry. 2023;23:587 https:\/\/doi.org\/10.1186\/s12888-023-05017-y.","journal-title":"BMC Psychiatry"},{"key":"3722_CR13","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1007\/s40263-018-0519-3","volume":"32","author":"P Molero","year":"2018","unstructured":"Molero P, Ramos-Quiroga JA, Martin-Santos R, Calvo-S\u00e1nchez E, Guti\u00e9rrez-Rojas L, Meana JJ. Antidepressant efficacy and tolerability of ketamine and esketamine: a critical review. CNS Drugs. 2018;32:411\u201320. https:\/\/doi.org\/10.1007\/s40263-018-0519-3.","journal-title":"CNS Drugs"},{"key":"3722_CR14","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1176\/appi.ajp.2020.20081251","volume":"178","author":"RS McIntyre","year":"2021","unstructured":"McIntyre RS, Rosenblat JD, Nemeroff CB, Sanacora G, Murrough JW, Berk M, et al. Synthesizing the evidence for ketamine and esketamine in treatment-resistant depression: an international expert opinion on the available evidence and implementation. Am J Psychiatry. 2021;178:383\u201399. https:\/\/doi.org\/10.1176\/appi.ajp.2020.20081251.","journal-title":"Am J Psychiatry"},{"key":"3722_CR15","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1001\/jamapsychiatry.2025.3019","volume":"82","author":"A Jelovac","year":"2025","unstructured":"Jelovac A, McCaffrey C, Terao M, Shanahan E, Whooley E, McDonagh K, et al. Serial ketamine infusions as adjunctive therapy to inpatient care for depression: The KARMA-Dep 2 randomized clinical trial. JAMA Psychiatry. 2025;82:1216\u201324. https:\/\/doi.org\/10.1001\/jamapsychiatry.2025.3019.","journal-title":"JAMA Psychiatry"},{"key":"3722_CR16","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.neuropharm.2017.12.040","volume":"142","author":"JJH Rucker","year":"2018","unstructured":"Rucker JJH, Iliff J, Nutt DJ. Psychiatry & the psychedelic drugs. Past, present & future. Neuropharmacology. 2018;142:200\u201318. https:\/\/doi.org\/10.1016\/j.neuropharm.2017.12.040.","journal-title":"Neuropharmacology"},{"key":"3722_CR17","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.cell.2020.03.020","volume":"181","author":"D Nutt","year":"2020","unstructured":"Nutt D, Erritzoe D, Carhart-Harris R. Psychedelic psychiatry\u2019s brave new world. Cell. 2020;181:24\u201328. https:\/\/doi.org\/10.1016\/j.cell.2020.03.020.","journal-title":"Cell"},{"key":"3722_CR18","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1001\/jamapsychiatry.2020.2171","volume":"78","author":"D Nutt","year":"2021","unstructured":"Nutt D, Carhart-Harris R. The current status of psychedelics in psychiatry. JAMA Psychiatry. 2021;78:121\u20132. https:\/\/doi.org\/10.1001\/jamapsychiatry.2020.2171.","journal-title":"JAMA Psychiatry"},{"key":"3722_CR19","unstructured":"Brooks M FDA grants psilocybin second breakthrough terapy designation for resistant depression. Medscape. 2019 [cited 2020 Jun 3]. https:\/\/www.medscape.com\/viewarticle\/921789."},{"key":"3722_CR20","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1177\/02698811231158891","volume":"37","author":"T Cooper","year":"2023","unstructured":"Cooper T, Seigler MD, Stahl S. Rapid onset brain plasticity at novel pharmacologic targets hypothetically drives innovations for rapid onset antidepressant actions. J Psychopharmacol. 2023;37:242\u20137. https:\/\/doi.org\/10.1177\/02698811231158891.","journal-title":"J Psychopharmacol"},{"key":"3722_CR21","unstructured":"Ravindran AS, Wang C, Avissar M, Rose M, Sundar G, Badami F et al. Neural correlates of an EEG biomarker predictive of the antidepressant response to ALTO-300 in patients with major depression. Poster presented at: 63rd Annual Meeting of the American College of Neuropsychopharmacology (ACNP); December 8\u201311, 2024; Phoenix, AZ"},{"key":"3722_CR22","unstructured":"Spear MA, Luo W, Chen C, Mumenthaler M, Alphs L Use of a novel pharmacogenomic biomarker to enrich responders to liafensine in treatment resistant depression (TRD) in a phase 2b Clinical Trial (ENLIGHTEN). Poster presented at:International Society for CNS Clinical Trials and Methodology (ISCTM) Annual Meeting; September 12-13, 2024; San Diego, CA."},{"key":"3722_CR23","doi-asserted-by":"publisher","first-page":"3170","DOI":"10.1016\/j.celrep.2018.05.022","volume":"23","author":"C Ly","year":"2018","unstructured":"Ly C, Greb AC, Cameron LP, Wong JM, Barragan EV, Wilson PC, et al. Psychedelics promote structural and functional neural plasticity. Cell Rep. 2018;23:3170\u201382. https:\/\/doi.org\/10.1016\/j.celrep.2018.05.022.","journal-title":"Cell Rep"},{"key":"3722_CR24","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1124\/pr.118.017160","volume":"71","author":"RL Carhart-Harris","year":"2019","unstructured":"Carhart-Harris RL, Friston KJ. REBUS and the anarchic brain: toward a unified model of the brain action of psychedelics. Pharmacol Rev. 2019;71:316\u201344. https:\/\/doi.org\/10.1124\/pr.118.017160.","journal-title":"Pharmacol Rev"},{"key":"3722_CR25","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/S2215-0366(16)30065-7","volume":"3","author":"RL Carhart-Harris","year":"2016","unstructured":"Carhart-Harris RL, Bolstridge M, Rucker J, Day CM, Erritzoe D, Kaelen M, et al. Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. Lancet Psychiatry. 2016;3:619\u201327. https:\/\/doi.org\/10.1016\/S2215-0366(16)30065-7.","journal-title":"Lancet Psychiatry"},{"key":"3722_CR26","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1007\/s00213-017-4771-x","volume":"235","author":"RL Carhart-Harris","year":"2018","unstructured":"Carhart-Harris RL, Bolstridge M, Day CMJ, Rucker J, Watts R, Erritzoe DE, et al. Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. Psychopharmacology (Berl). 2018;235:399\u2013408. https:\/\/doi.org\/10.1007\/s00213-017-4771-x.","journal-title":"Psychopharmacology (Berl)"},{"key":"3722_CR27","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.cub.2016.12.030","volume":"27","author":"KH Preller","year":"2017","unstructured":"Preller KH, Herdener M, Pokorny T, Planzer A, Kraehenmann R, St\u00e4mpfli P, et al. The fabric of meaning and subjective effects in LSD-induced states depend on serotonin 2A receptor activation. Curr Biol. 2017;27:451\u20137. https:\/\/doi.org\/10.1016\/j.cub.2016.12.030.","journal-title":"Curr Biol"},{"key":"3722_CR28","doi-asserted-by":"publisher","first-page":"3603","DOI":"10.1523\/JNEUROSCI.1939-17.2018","volume":"38","author":"KH Preller","year":"2018","unstructured":"Preller KH, Schilbach L, Pokorny T, Flemming J, Seifritz E, Vollenweider FX. Role of the 5-HT2A receptor in self- and other-initiated social interaction in lysergic acid diethylamide-induced states: a pharmacological fMRI study. J Neurosci. 2018;38:3603\u201311. https:\/\/doi.org\/10.1523\/JNEUROSCI.1939-17.2018.","journal-title":"J Neurosci"},{"key":"3722_CR29","doi-asserted-by":"publisher","first-page":"814","DOI":"10.3389\/fphar.2017.00814","volume":"8","author":"R Kraehenmann","year":"2017","unstructured":"Kraehenmann R, Pokorny D, Aicher H, Preller KH, Pokorny T, Bosch OG, et al. LSD increases primary process thinking via serotonin 2A receptor activation. Front Pharmacol. 2017;8:814 https:\/\/doi.org\/10.3389\/fphar.2017.00814.","journal-title":"Front Pharmacol"},{"key":"3722_CR30","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1007\/s00213-017-4610-0","volume":"234","author":"R Kraehenmann","year":"2017","unstructured":"Kraehenmann R, Pokorny D, Vollenweider L, Preller KH, Pokorny T, Seifritz E, et al. Dreamlike effects of LSD on waking imagery in humans depend on serotonin 2A receptor activation. Psychopharmacology (Berl). 2017;234:2031\u201346. https:\/\/doi.org\/10.1007\/s00213-017-4610-0.","journal-title":"Psychopharmacology (Berl)"},{"key":"3722_CR31","doi-asserted-by":"publisher","first-page":"3897","DOI":"10.1097\/00001756-199812010-00024","volume":"9","author":"FX Vollenweider","year":"1998","unstructured":"Vollenweider FX, Vollenweider-Scherpenhuyzen MF, B\u00e4bler A, Vogel H, Hell D. Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. Neuroreport. 1998;9:3897\u2013902. https:\/\/doi.org\/10.1097\/00001756-199812010-00024.","journal-title":"Neuroreport"},{"key":"3722_CR32","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1038\/s41386-019-0324-9","volume":"44","author":"MK Madsen","year":"2019","unstructured":"Madsen MK, Fisher PM, Burmester D, Dyssegaard A, Stenb\u00e6k DS, Kristiansen S, et al. Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels. Neuropsychopharmacology. 2019;44:1328\u201334. https:\/\/doi.org\/10.1038\/s41386-019-0324-9. Epub 2019 Jan 26. Erratum in: Neuropsychopharmacology. 2019 Jun;44(7):1336-1337.","journal-title":"Neuropsychopharmacology"},{"key":"3722_CR33","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/S0893-133X(98)00108-0","volume":"20","author":"FX Vollenweider","year":"1999","unstructured":"Vollenweider FX, Vontobel P, Hell D, Leenders KL. 5-HT modulation of dopamine release in basal ganglia in psilocybin-induced psychosis in man\u2013a PET study with [11C]raclopride. Neuropsychopharmacology. 1999;20:424\u201333. https:\/\/doi.org\/10.1016\/S0893-133X(98)00108-0.","journal-title":"Neuropsychopharmacology"},{"key":"3722_CR34","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/s0006-8993(99)02346-x","volume":"858","author":"J Ichikawa","year":"2000","unstructured":"Ichikawa J, Meltzer HY. The effect of serotonin(1A) receptor agonism on antipsychotic drug-induced dopamine release in rat striatum and nucleus accumbens. Brain Res. 2000;858:252\u201363. https:\/\/doi.org\/10.1016\/s0006-8993(99)02346-x.","journal-title":"Brain Res"},{"key":"3722_CR35","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1038\/nrn2884","volume":"11","author":"F Vollenweider","year":"2010","unstructured":"Vollenweider F, Kometer M. The neurobiology of psychedelic drugs: implications for the treatment of mood disorders. Nat Rev Neurosci. 2010;11:642\u201351. https:\/\/doi.org\/10.1038\/nrn2884.","journal-title":"Nat Rev Neurosci"},{"key":"3722_CR36","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1021\/acs.biochem.1c00812","volume":"61","author":"DE Olson","year":"2022","unstructured":"Olson DE. Biochemical mechanisms underlying psychedelic-induced neuroplasticity. Biochemistry. 2022;61:127\u201336. https:\/\/doi.org\/10.1021\/acs.biochem.1c00812.","journal-title":"Biochemistry"},{"key":"3722_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2023.115531","volume":"329","author":"S Haikazian","year":"2023","unstructured":"Haikazian S, Chen-Li DCJ, Johnson DE, Fancy F, Levinta A, Husain MI, et al. Psilocybin-assisted therapy for depression: A systematic review and meta-analysis. Psychiatry Res. 2023;329:115531 https:\/\/doi.org\/10.1016\/j.psychres.2023.115531.","journal-title":"Psychiatry Res"},{"key":"3722_CR38","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1056\/NEJMoa2206443","volume":"387","author":"GM Goodwin","year":"2022","unstructured":"Goodwin GM, Aaronson ST, Alvarez O, Arden PC, Baker A, Bennett JC, et al. Single-dose psilocybin for a treatment-resistant episode of major depression. N Engl J Med. 2022;387:1637\u201348.","journal-title":"N Engl J Med"},{"key":"3722_CR39","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1001\/jama.2023.14530","volume":"330","author":"CL Raison","year":"2023","unstructured":"Raison CL, Sanacora G, Woolley J, Heinzerling K, Dunlop BW, Brown RT, et al. Single-dose psilocybin treatment for major depressive disorder: a randomized clinical trial. JAMA. 2023;330:843\u201353. https:\/\/doi.org\/10.1001\/jama.2023.14530. Erratum in: JAMA. 2024 Feb 27;331(8):710","journal-title":"JAMA"},{"key":"3722_CR40","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1185\/030079908x291958","volume":"24","author":"G Duru","year":"2008","unstructured":"Duru G, Fantino B. The clinical relevance of changes in the Montgomery-Asberg Depression Rating Scale using the minimum clinically important difference approach. Curr Med Res Opin. 2008;24:1329\u201335. https:\/\/doi.org\/10.1185\/030079908x291958.","journal-title":"Curr Med Res Opin"},{"key":"3722_CR41","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.jpsychires.2014.01.005","volume":"51","author":"A Khan","year":"2014","unstructured":"Khan A, Faucett J, Brown WA. Magnitude of placebo response and response variance in antidepressant clinical trials using structured, taped and appraised rater interviews compared to traditional rating interviews. J Psychiatr Res. 2014;51:88\u201392. https:\/\/doi.org\/10.1016\/j.jpsychires.2014.01.005.","journal-title":"J Psychiatr Res"},{"key":"3722_CR42","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1038\/s41386-023-01648-7","volume":"48","author":"GM Goodwin","year":"2023","unstructured":"Goodwin GM, Croal M, Feifel D, Kelly JR, Marwood L, Mistry S, et al. Psilocybin for treatment resistant depression in patients taking a concomitant SSRI medication. Neuropsychopharmacology. 2023;48:1492\u20139. https:\/\/doi.org\/10.1038\/s41386-023-01648-7.","journal-title":"Neuropsychopharmacology"},{"key":"3722_CR43","doi-asserted-by":"publisher","first-page":"24m15449","DOI":"10.4088\/JCP.24m15449","volume":"86","author":"GM Goodwin","year":"2025","unstructured":"Goodwin GM, Nowakowska A, Atli M, Dunlop BW, Feifel D, Hellerstein DJ, et al. Results from a long-term observational follow-up study of a single dose of psilocybin for a treatment-resistant episode of major depressive disorder. J Clin Psychiatry. 2025;86:24m15449 https:\/\/doi.org\/10.4088\/JCP.24m15449.","journal-title":"J Clin Psychiatry"},{"key":"3722_CR44","unstructured":"Compass Pathways. (2025, June 23). Compass Pathways Successfully Achieves Primary Endpoint in First Phase 3 Trial Evaluating COMP360 Psilocybin for Treatment-Resistant Depression. Business Wire. Retrieved from https:\/\/www.businesswire.com\/news\/home\/20250623615674\/en\/Compass-Pathways-Successfully-Achieves-Primary-Endpoint-in-First-Phase-3-Trial-Evaluating-COMP360-Psilocybin-for-Treatment-Resistant-Depression."},{"key":"3722_CR45","unstructured":"Compass Pathways. (2026, March 31). Compass Pathways Successfully Achieves Primary Endpoint in Second Phase 3 Trial Evaluating COMP360 Psilocybin for Treatment-Resistant Depression. Retrieved from https:\/\/ir.compasspathways.com\/News--Events-\/news\/news-details\/2026\/Compass-Pathways-Successfully-Achieves-Primary-Endpoint-in-Second-Phase-3-Trial-Evaluating-COMP360-Psilocybin-for-Treatment-Resistant-Depression\/default.aspx."},{"key":"3722_CR46","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1056\/NEJMoa2032994","volume":"384","author":"R Carhart-Harris","year":"2021","unstructured":"Carhart-Harris R, Giribaldi B, Watts R, Baker-Jones M, Murphy-Beiner A, Murphy R, et al. Trial of psilocybin versus escitalopram for depression. N Engl J Med. 2021;384:1402\u201311. https:\/\/doi.org\/10.1056\/NEJMoa2032994.","journal-title":"N Engl J Med"},{"key":"3722_CR47","unstructured":"Krempien S, Inamdar A, Shenouda ML, Johnson K, Ann Maass-Robinson S, Johnson M et al. Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of CYB003, a Deuterated Psilocybin Analog in Patients with Major Depressive Disorder. Poster presented at: 62nd Annual Meeting of the American College of Neuropsychopharmacology (ACNP); December 3-6, 2023; Tampa, Fl."},{"key":"3722_CR48","unstructured":"Inamdar A, Krempien S, Kelman A, Mahableshwarkar A, Shenouda M, Johnson K et al. CYB003 Produces Robust and Enduring Antidepressant Effects in Patients With Major Depressive Disorder (MDD). Poster presented at: 63nd Annual Meeting of the American College of Neuropsychopharmacology (ACNP); December 8-11, 2024; Phoenix, Az."},{"key":"3722_CR49","unstructured":"Beckley Psytech. (2024, December 16). Beckley Psytech announces positive topline results from Phase IIa study of ELE-101 (IV psilocin benzoate) for Major Depressive Disorder [Press release]. https:\/\/www.beckleypsytech.com\/posts\/beckley-psytech-announces-positive-topline-results-from-phase-iia-study-of-ele-101-for-major-depressive-disorder."},{"key":"3722_CR50","doi-asserted-by":"publisher","unstructured":"Mertens LJ, Koslowski M, Betzler F, Brand M, Evens R, K\u00e4rtner L et al. Efficacy and safety of psilocybin in treatment-resistant major depression: The EPISODE randomized clinical trial. JAMA Psychiatry. Published online March 18, 2026. https:\/\/doi.org\/10.1001\/jamapsychiatry.2026.0132.","DOI":"10.1001\/jamapsychiatry.2026.0132"},{"key":"3722_CR51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jad.2023.02.030","volume":"328","author":"GM Goodwin","year":"2023","unstructured":"Goodwin GM, Croal M, Marwood L, Malievskaia E. Unblinding and demand characteristics in the treatment of depression. J Affect Disord. 2023;328:1\u20135. https:\/\/doi.org\/10.1016\/j.jad.2023.02.030.","journal-title":"J Affect Disord"},{"key":"3722_CR52","doi-asserted-by":"publisher","first-page":"e067606","DOI":"10.1136\/bmj-2021-067606","volume":"378","author":"MB Stone","year":"2022","unstructured":"Stone MB, Yaseen ZS, Miller BJ, Richardville K, Kalaria SN, Kirsch I. Response to acute monotherapy for major depressive disorder in randomized, placebo controlled trials submitted to the US Food and Drug Administration: individual participant data analysis. BMJ. 2022;378:e067606 https:\/\/doi.org\/10.1136\/bmj-2021-067606.","journal-title":"BMJ"},{"key":"3722_CR53","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1124\/pr.115.011478","volume":"68","author":"DE Nichols","year":"2016","unstructured":"Nichols DE. Psychedelics. Pharmacol Rev. 2016;68:264\u2013355. https:\/\/doi.org\/10.1124\/pr.115.011478. Erratum in: Pharmacol Rev. 2016 Apr;68(2):356. doi: 10.1124\/pr.114.011478err. PMID: 26841800; PMCID: PMC4813425.","journal-title":"Pharmacol Rev"},{"key":"3722_CR54","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1007\/s00213-011-2616-6","volume":"221","author":"AL Halberstadt","year":"2012","unstructured":"Halberstadt AL, Nichols DE, Geyer MA. Behavioral effects of \u03b1,\u03b1,\u03b2,\u03b2-tetradeutero-5-MeO-DMT in rats: comparison with 5-MeO-DMT administered in combination with a monoamine oxidase inhibitor. Psychopharmacology (Berl). 2012;221:709\u201318. https:\/\/doi.org\/10.1007\/s00213-011-2616-6.","journal-title":"Psychopharmacology (Berl)"},{"key":"3722_CR55","unstructured":"Beckley Psytech. (2024, March 27). Beckley Psytech announces positive initial data from Phase IIa study of novel 5-MeO-DMT formulation BPL-003 for Treatment Resistant Depression [Press release]. https:\/\/www.beckleypsytech.com\/posts\/beckley-psytech-announces-positive-initial-data-from-phase-iia-study-of-bpl-003-for-treatment-resistant-depression."},{"key":"3722_CR56","doi-asserted-by":"publisher","unstructured":"Cubala WJ, Bajbouj M, Bauer M, Baune BT, Cardoner N, Devlin F et al. GH001 vs placebo in patients with treatment-resistant depression: a randomized clinical trial. JAMA Psychiatry. 2026:e260096. https:\/\/doi.org\/10.1001\/jamapsychiatry.2026.0096.","DOI":"10.1001\/jamapsychiatry.2026.0096"},{"key":"3722_CR57","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.24com15504","volume":"85","author":"JF Rosenbaum","year":"2024","unstructured":"Rosenbaum JF. Functional unblinding in pivotal studies and the future of psychedelic medicine. J Clin Psychiatry. 2024;85:24com15504 https:\/\/doi.org\/10.4088\/JCP.24com15504.","journal-title":"J Clin Psychiatry"},{"key":"3722_CR58","unstructured":"Marek JG, Umbricht D, Christian EP, Winters J, Raines S, Leong W et al. Robust antidepressant efficacy of the novel 5-HT2A receptor agonist GM-2505 in a double-blind, randomized, controlled, phase 2a trial in patients with MDD. Poster presented at: the American Society Clinical Psychopharmacology (ASCP) Annual Meeting, May 27-30, 2025; Scottsdale, Az."},{"key":"3722_CR59","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1038\/s41591-025-04154-z","volume":"32","author":"D Erritzoe","year":"2026","unstructured":"Erritzoe D, Barba T, Benway T, Joel Z, Good M, Layzell M, et al. A short-acting psychedelic intervention for major depressive disorder: a phase IIa randomized placebo-controlled trial. Nat Med. 2026;32:591\u20138. https:\/\/doi.org\/10.1038\/s41591-025-04154-z.","journal-title":"Nat Med"},{"key":"3722_CR60","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1001\/jama.2025.13481","volume":"334","author":"R Robison","year":"2025","unstructured":"Robison R, Barrow R, Conant C, Foster E, Freedman JM, Jacobsen PL, et al. Single treatment with MM120 (Lysergide) in generalized anxiety disorder: a randomized clinical trial. JAMA. 2025;334:1358\u201372. https:\/\/doi.org\/10.1001\/jama.2025.13481.","journal-title":"JAMA"},{"key":"3722_CR61","doi-asserted-by":"publisher","DOI":"10.1002\/pcn5.146","volume":"2","author":"SGD Ruffell","year":"2023","unstructured":"Ruffell SGD, Crosland-Wood M, Palmer R, Netzband N, Tsang W, Weiss B, et al. Ayahuasca: A review of historical, pharmacological, and therapeutic aspects. PCN Rep. 2023;2:e146 https:\/\/doi.org\/10.1002\/pcn5.146.","journal-title":"PCN Rep"},{"key":"3722_CR62","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/s0091-3057(98)00110-5","volume":"61","author":"RL Smith","year":"1998","unstructured":"Smith RL, Canton H, Barrett RJ, Sanders-Bush E. Agonist properties of N,N-dimethyltryptamine at serotonin 5-HT2A and 5-HT2C receptors. Pharmacol Biochem Behav. 1998;61:323\u201330. https:\/\/doi.org\/10.1016\/s0091-3057(98)00110-5.","journal-title":"Pharmacol Biochem Behav"},{"key":"3722_CR63","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1017\/S0033291718001356","volume":"49","author":"F Palhano-Fontes","year":"2019","unstructured":"Palhano-Fontes F, Barreto D, Onias H, Andrade KC, Novaes MM, Pessoa JA, et al. Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial. Psychol Med. 2019;49:655\u201363. https:\/\/doi.org\/10.1017\/S0033291718001356.","journal-title":"Psychol Med"},{"key":"3722_CR64","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1080\/00952990.2017.1310218","volume":"44","author":"GE Noller","year":"2018","unstructured":"Noller GE, Frampton CM, Yazar-Klosinski B. Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study. Am J Drug Alcohol Abuse. 2018;44:37\u201346. https:\/\/doi.org\/10.1080\/00952990.2017.1310218.","journal-title":"Am J Drug Alcohol Abuse"},{"key":"3722_CR65","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2021.108717","volume":"138","author":"P K\u00f6ck","year":"2022","unstructured":"K\u00f6ck P, Froelich K, Walter M, Lang U, D\u00fcrsteler KM. A systematic literature review of clinical trials and therapeutic applications of ibogaine. J Subst Abuse Treat. 2022;138:108717 https:\/\/doi.org\/10.1016\/j.jsat.2021.108717.","journal-title":"J Subst Abuse Treat"},{"key":"3722_CR66","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1556\/2054.01.2017.009","volume":"1","author":"AK Davis","year":"2017","unstructured":"Davis AK, Barsuglia JP, Windham-Herman AM, Lynch M, Polanco M. Subjective effectiveness of ibogaine treatment for problematic opioid consumption: Short- and long-term outcomes and current psychological functioning. J Psychedelic Stud. 2017;1:65\u201373. https:\/\/doi.org\/10.1556\/2054.01.2017.009.","journal-title":"J Psychedelic Stud"},{"key":"3722_CR67","doi-asserted-by":"publisher","DOI":"10.1177\/2470547020939564","volume":"4","author":"AK Davis","year":"2020","unstructured":"Davis AK, Averill LA, Sepeda ND, Barsuglia JP, Amoroso T. Psychedelic treatment for trauma-related psychological and cognitive impairment among US special operations forces veterans. Chronic Stress (Thousand Oaks). 2020;4:2470547020939564 https:\/\/doi.org\/10.1177\/2470547020939564.","journal-title":"Chronic Stress (Thousand Oaks)"},{"key":"3722_CR68","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1080\/02791072.2019.1598603","volume":"51","author":"TK Brown","year":"2019","unstructured":"Brown TK, Noller GE, Denenberg JO. Ibogaine and subjective experience: transformative states and psychopharmacotherapy in the treatment of opioid use disorder. J Psychoactive Drugs. 2019;51:155\u201365. https:\/\/doi.org\/10.1080\/02791072.2019.1598603.","journal-title":"J Psychoactive Drugs"},{"key":"3722_CR69","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1111\/j.1749-6632.2000.tb05213.x","volume":"914","author":"DC Mash","year":"2000","unstructured":"Mash DC, Kovera CA, Pablo J, Tyndale RF, Ervin FD, Williams IC, et al. Ibogaine: complex pharmacokinetics, concerns for safety, and preliminary efficacy measures. Ann N Y Acad Sci. 2000;914:394\u2013401. https:\/\/doi.org\/10.1111\/j.1749-6632.2000.tb05213.x.","journal-title":"Ann N Y Acad Sci"},{"key":"3722_CR70","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/s0099-9598(01)56012-5","volume":"56","author":"DC Mash","year":"2001","unstructured":"Mash DC, Kovera CA, Pablo J, Tyndale R, Ervin FR, Kamlet JD, et al. Ibogaine in the treatment of heroin withdrawal. Alkaloids Chem Biol. 2001;56:155\u201371. https:\/\/doi.org\/10.1016\/s0099-9598(01)56012-5.","journal-title":"Alkaloids Chem Biol"},{"key":"3722_CR71","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/00952990.2017.1357184","volume":"44","author":"D C Mash","year":"2018","unstructured":"C Mash D. Breaking the cycle of opioid use disorder with Ibogaine. Am J Drug Alcohol Abuse. 2018;44:1\u20133. https:\/\/doi.org\/10.1080\/00952990.2017.1357184.","journal-title":"Am J Drug Alcohol Abuse"},{"key":"3722_CR72","doi-asserted-by":"publisher","DOI":"10.1177\/20451253231198466","volume":"13","author":"M Van Elk","year":"2023","unstructured":"Van Elk M, Fried EI. History repeating: guidelines to address common problems in psychedelic science. Ther Adv Psychopharmacol. 2023;13:20451253231198466 https:\/\/doi.org\/10.1177\/20451253231198466. Erratum in: Ther Adv Psychopharmacol. 2024 Jan 10;14:20451253231223609. PMID: 37766730; PMCID: PMC10521293.","journal-title":"Ther Adv Psychopharmacol"},{"key":"3722_CR73","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1001\/jamapsychiatry.2025.0442","volume":"82","author":"ST Wilkinson","year":"2025","unstructured":"Wilkinson ST, Sanacora G. Issues in clinical trial design-lessons from the FDA\u2019s rejection of MDMA. JAMA Psychiatry. 2025;82:545\u20136. https:\/\/doi.org\/10.1001\/jamapsychiatry.2025.0442.","journal-title":"JAMA Psychiatry"},{"key":"3722_CR74","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1001\/jamapsychiatry.2022.2096","volume":"79","author":"MP Bogenschutz","year":"2022","unstructured":"Bogenschutz MP, Ross S, Bhatt S, Baron T, Forcehimes AA, Laska E, et al. Percentage of heavy drinking days following psilocybin-assisted psychotherapy vs placebo in the treatment of adult patients with alcohol use disorder: a randomized clinical trial. JAMA Psychiatry. 2022;79:953\u201362. https:\/\/doi.org\/10.1001\/jamapsychiatry.2022.2096. Erratum in: JAMA Psychiatry. 2022 Sep 14. doi: 10.1001\/jamapsychiatry.2022.2982. PMID: 36001306; PMCID: PMC9403854.","journal-title":"JAMA Psychiatry"},{"key":"3722_CR75","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/s0005-7916(00)00012-4","volume":"31","author":"GJ Devilly","year":"2000","unstructured":"Devilly GJ, Borkovec TD. Psychometric properties of the credibility\/expectancy questionnaire. J Behav Ther Exp Psychiatry. 2000;31:73\u201386. https:\/\/doi.org\/10.1016\/s0005-7916(00)00012-4.","journal-title":"J Behav Ther Exp Psychiatry"},{"key":"3722_CR76","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.bpsc.2024.02.004","volume":"9","author":"B Szigeti","year":"2024","unstructured":"Szigeti B, Heifets BD. Expectancy effects in psychedelic trials. Biol Psychiatry Cogn Neurosci Neuroimaging. 2024;9:512\u201321. https:\/\/doi.org\/10.1016\/j.bpsc.2024.02.004.","journal-title":"Biol Psychiatry Cogn Neurosci Neuroimaging"},{"key":"3722_CR77","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1001\/jamapsychiatry.2025.0085","volume":"82","author":"NTM Huneke","year":"2025","unstructured":"Huneke NTM, Fusetto Veronesi G, Garner M, Baldwin DS, Cortese S. Expectancy effects, failure of blinding integrity, and placebo response in trials of treatments for psychiatric disorders: a narrative review. JAMA Psychiatry. 2025;82:531\u20138. https:\/\/doi.org\/10.1001\/jamapsychiatry.2025.0085.","journal-title":"JAMA Psychiatry"},{"key":"3722_CR78","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-023-02473-8","volume":"13","author":"MJ Shram","year":"2023","unstructured":"Shram MJ, Henningfield JE, Apseloff G, Gorodetzky CW, De Martin S, Vocci FL, et al. The novel uncompetitive NMDA receptor antagonist esmethadone (REL-1017) has no meaningful abuse potential in recreational drug users. Transl Psychiatry. 2023;13:192 https:\/\/doi.org\/10.1038\/s41398-023-02473-8.","journal-title":"Transl Psychiatry"},{"key":"3722_CR79","doi-asserted-by":"publisher","first-page":"e078084","DOI":"10.1136\/bmj.r111","volume":"385","author":"AM Metaxa","year":"2024","unstructured":"Metaxa AM, Clarke M. Efficacy of psilocybin for treating symptoms of depression: systematic review and meta-analysis. BMJ. 2024;385:e078084 https:\/\/doi.org\/10.1136\/bmj.r111. Erratum in: BMJ. 2025;388:r111PMID: 38692686; PMCID:PMC11062320.","journal-title":"BMJ"},{"key":"3722_CR80","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2022.1025726","volume":"13","author":"E Marseille","year":"2022","unstructured":"Marseille E, Bertozzi S, Kahn JG. The economics of psychedelic-assisted therapies: A research agenda. Front Psychiatry. 2022;13:1025726 https:\/\/doi.org\/10.3389\/fpsyt.2022.1025726.","journal-title":"Front Psychiatry"},{"key":"3722_CR81","doi-asserted-by":"publisher","first-page":"1293243","DOI":"10.3389\/fpsyt.2023.1293243","volume":"14","author":"E Marseille","year":"2023","unstructured":"Marseille E, Stauffer CS, Agrawal M, Thambi P, Roddy K, Mithoefer M, et al. Group psychedelic therapy: empirical estimates of cost-savings and improved access. Front Psychiatry. 2023;14:1293243 https:\/\/doi.org\/10.3389\/fpsyt.2023.1293243.","journal-title":"Front Psychiatry"},{"key":"3722_CR82","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1097\/01.NAJ.0000753464.35523.29","volume":"121","author":"A Penn","year":"2021","unstructured":"Penn A, Dorsen CG, Hope S, Rosa WE. Psychedelic-assisted therapy: emerging treatments in mental health disorders. Am J Nurs. 2021;121:34\u201340. https:\/\/doi.org\/10.1097\/01.NAJ.0000753464.35523.29.","journal-title":"Am J Nurs"},{"key":"3722_CR83","doi-asserted-by":"publisher","DOI":"10.1186\/s12909-025-06871-y","volume":"25","author":"HD Aicher","year":"2025","unstructured":"Aicher HD, M\u00fcller F, Gasser P. Further education in psychedelic-assisted therapy - experiences from Switzerland. BMC Med Educ. 2025;25:341 https:\/\/doi.org\/10.1186\/s12909-025-06871-y.","journal-title":"BMC Med Educ"},{"key":"3722_CR84","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-53188-9","volume":"14","author":"JJ Breeksema","year":"2024","unstructured":"Breeksema JJ, Niemeijer A, Krediet E, Karsten T, Kamphuis J, Vermetten E, et al. Patient perspectives and experiences with psilocybin treatment for treatment-resistant depression: a qualitative study. Sci Rep. 2024;14:2929 https:\/\/doi.org\/10.1038\/s41598-024-53188-9.","journal-title":"Sci Rep"},{"key":"3722_CR85","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-018-1625-y","volume":"18","author":"R Mago","year":"2018","unstructured":"Mago R, Fagiolini A, Weiller E, Weiss C. Understanding the emotions of patients with inadequate response to antidepressant treatments: results of an international online survey in patients with major depressive disorder. BMC Psychiatry. 2018;18:33 https:\/\/doi.org\/10.1186\/s12888-018-1625-y.","journal-title":"BMC Psychiatry"},{"key":"3722_CR86","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/00221678221081380","volume":"62","author":"S Thal","year":"2022","unstructured":"Thal S, Engel LB, Bright SJ. Presence, trust, and empathy: preferred characteristics of psychedelic carers. J Hum Psychol. 2022;62:1\u201324. https:\/\/doi.org\/10.1177\/00221678221081380.","journal-title":"J Hum Psychol"},{"key":"3722_CR87","doi-asserted-by":"publisher","first-page":"e99","DOI":"10.1017\/S0033291725000716","volume":"55","author":"O Simonsson","year":"2025","unstructured":"Simonsson O, Goldberg SB, Osika W, Stenfors CUD, Chaturvedi S, Swords CM, et al. Longitudinal associations of naturalistic psychedelic use with psychotic and manic symptoms. Psychol Med. 2025;55:e99 https:\/\/doi.org\/10.1017\/S0033291725000716.","journal-title":"Psychol Med"},{"key":"3722_CR88","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1001\/jamapsychiatry.2024.0047","volume":"81","author":"O Simonsson","year":"2024","unstructured":"Simonsson O, Mosing MA, Osika W, Ull\u00e9n F, Larsson H, Lu Y, et al. Adolescent psychedelic use and psychotic or manic symptoms. JAMA Psychiatry. 2024;81:579\u201385. https:\/\/doi.org\/10.1001\/jamapsychiatry.2024.0047.","journal-title":"JAMA Psychiatry"},{"key":"3722_CR89","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1177\/02698811211073759","volume":"36","author":"N Gukasyan","year":"2022","unstructured":"Gukasyan N, Davis AK, Barrett FS, Cosimano MP, Sepeda ND, Johnson MW, et al. Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up. J Psychopharmacol. 2022;36:151\u20138.","journal-title":"J Psychopharmacol"},{"key":"3722_CR90","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1038\/s44220-024-00233-1","volume":"2","author":"JC Black","year":"2024","unstructured":"Black JC, Monte AA, Dasgupta N. Optimizing real-world benefit and risk of new psychedelic medications: the need for innovative postmarket surveillance. Nat. Mental Health. 2024;2:469\u201377. https:\/\/doi.org\/10.1038\/s44220-024-00233-1.","journal-title":"Nat. Mental Health"},{"key":"3722_CR91","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1001\/jamapsychiatry.2024.2546","volume":"81","author":"JT Hinkle","year":"2024","unstructured":"Hinkle JT, Graziosi M, Nayak SM, Yaden DB. Adverse events in studies of classic psychedelics: a systematic review and meta-analysis. JAMA Psychiatry. 2024;81:1225\u201335. https:\/\/doi.org\/10.1001\/jamapsychiatry.2024.2546.","journal-title":"JAMA Psychiatry"},{"key":"3722_CR92","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2025.103517","volume":"89","author":"MM Hosein","year":"2025","unstructured":"Hosein MM, Reid MJ, Walser S, Charney S, Fonzo GA, Lewis BR, et al. Considerations and cautions for the integration of psilocybin into routine clinical care: a consensus statement from the US National Network of Depression Centers\u2019 Task Group on Psychedelics and Related Compounds. EClinicalMedicine. 2025;89:103517 https:\/\/doi.org\/10.1016\/j.eclinm.2025.103517.","journal-title":"EClinicalMedicine"},{"key":"3722_CR93","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1001\/jamapsychiatry.2025.2240","volume":"82","author":"ECC Smith","year":"2025","unstructured":"Smith ECC, Agarwal SM, Panganiban KJ, Maksyutynska K, Monteiro J, Lee J, et al. Antipsychotic drugs and dysregulated glucose homeostasis: a systematic review and meta-analysis. JAMA Psychiatry. 2025;82:977\u201391. https:\/\/doi.org\/10.1001\/jamapsychiatry.2025.2240.","journal-title":"JAMA Psychiatry"},{"key":"3722_CR94","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1176\/appi.ajp.2021.21020197","volume":"179","author":"M Fava","year":"2022","unstructured":"Fava M, Stahl S, Pani L, De Martin S, Pappagallo M, Guidetti C, et al. REL-1017 (Esmethadone) as adjunctive treatment in patients with major depressive disorder: a phase 2a randomized double-blind trial. Am J Psychiatry. 2022;179:122\u201331. https:\/\/doi.org\/10.1176\/appi.ajp.2021.21020197.","journal-title":"Am J Psychiatry"},{"key":"3722_CR95","doi-asserted-by":"publisher","first-page":"24m15265","DOI":"10.4088\/JCP.24m15265","volume":"85","author":"M Fava","year":"2024","unstructured":"Fava M, Stahl SM, Pani L, De Martin S, Cutler AJ, Maletic V, et al. Efficacy and safety of esmethadone (REL-1017) in patients with major depressive disorder and inadequate response to standard antidepressants: a phase 3 randomized controlled trial. J Clin Psychiatry. 2024;85:24m15265 https:\/\/doi.org\/10.4088\/JCP.24m15265.","journal-title":"J Clin Psychiatry"},{"key":"3722_CR96","doi-asserted-by":"publisher","unstructured":"Guidetti C, Papakostas GI, Stahl S, Pani L, De Martin S, Mattarei A et al. Depression severity and efficacy outcomes: post hoc analyses from a phase 3 trial of esmethadone for the adjunctive treatment of major depressive disorder with inadequate response to standard antidepressants. Int Clin Psychopharmacol. 2026. https:\/\/doi.org\/10.1097\/YIC.0000000000000618.","DOI":"10.1097\/YIC.0000000000000618"},{"key":"3722_CR97","doi-asserted-by":"publisher","first-page":"24m15748","DOI":"10.4088\/JCP.24m15748","volume":"86","author":"C Guidetti","year":"2025","unstructured":"Guidetti C, Papakostas GI, Pani L, De Martin S, Serra G, Apicella M, et al. Esmethadone (REL-1017) in patients with major depressive disorder and antidepressant tachyphylaxis: an exploratory post hoc analysis from a phase 3 randomized controlled trial. J Clin Psychiatry. 2025;86:24m15748 https:\/\/doi.org\/10.4088\/JCP.24m15748.","journal-title":"J Clin Psychiatry"},{"key":"3722_CR98","unstructured":"Guidetti C, Frigo AC, De Martin S, Mattarei A, Comai S, Pani L et al. Efficacy and Safety of Esmethadone (REL-1017) in Patients with Major Depressive Disorder and Inadequate Response to Standard Antidepressants: Findings from Two Early-Terminated Phase 3 Trials. Poster presented at: World Congress of Psychiatry, October 4-8, 2025; Prague, Czech Republic."},{"key":"3722_CR99","doi-asserted-by":"publisher","first-page":"24m15438","DOI":"10.4088\/JCP.24m15438","volume":"86","author":"M Fava","year":"2025","unstructured":"Fava M, Pani L, De Martin S, Cutler AJ, Gorodetzky CW, Vocci FJ, et al. Long-term safety and efficacy of esmethadone in patients with major depressive disorder: findings from a 12-month open-label study. J Clin Psychiatry. 2025;86:24m15438 https:\/\/doi.org\/10.4088\/JCP.24m15438.","journal-title":"J Clin Psychiatry"},{"key":"3722_CR100","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1097\/JCP.0000000000001035","volume":"39","author":"G Bernstein","year":"2019","unstructured":"Bernstein G, Davis K, Mills C, Wang L, McDonnell M, Oldenhof J, et al. Characterization of the safety and pharmacokinetic profile of D-Methadone, a Novel N-Methyl-D-Aspartate receptor antagonist in healthy, opioid-naive subjects: Results of two phase 1 studies. J Clin Psychopharmacol. 2019;39:226\u201337. https:\/\/doi.org\/10.1097\/JCP.0000000000001035.","journal-title":"J Clin Psychopharmacol"},{"key":"3722_CR101","unstructured":"DEA Drug Enforcement Administration: Drug and chemical information section: methadone.Springfield, VA, US Drug Enforcement Administration, Diversion, Control Division. https:\/\/www.deadiversion.usdoj.gov\/drug_chem_info\/methadone\/methadone.pdf."},{"key":"3722_CR102","doi-asserted-by":"publisher","first-page":"12196","DOI":"10.3390\/ijms232012196","volume":"23","author":"SM Stahl","year":"2022","unstructured":"Stahl SM, De Martin S, Mattarei A, Bettini E, Pani L, Guidetti C, et al. Esmethadone (REL-1017) and other uncompetitive NMDAR channel blockers may improve mood disorders via modulation of synaptic kinase-mediated signaling. Int J Mol Sci. 2022;23:12196 https:\/\/doi.org\/10.3390\/ijms232012196.","journal-title":"Int J Mol Sci"},{"key":"3722_CR103","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-66774-w","volume":"16","author":"S Vestring","year":"2025","unstructured":"Vestring S, Veleanu M, Perez MC, Schuberth LE, Bronnec M, Li A, et al. The NMDA receptor subunit GluN2D is a potential target for rapid antidepressant action. Nat Commun. 2025;16:10613 https:\/\/doi.org\/10.1038\/s41467-025-66774-w.","journal-title":"Nat Commun"},{"key":"3722_CR104","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1038\/s41386-023-01783-1","volume":"49","author":"AK Klein","year":"2024","unstructured":"Klein AK, Austin EW, Cunningham MJ, Dvorak D, Gatti S, Hulls SK, et al. A. GM-1020: a novel, orally bioavailable NMDA receptor antagonist with rapid and robust antidepressant-like effects at well-tolerated doses in rodents. Neuropsychopharmacology. 2024;49:905\u201314. https:\/\/doi.org\/10.1038\/s41386-023-01783-1.","journal-title":"Neuropsychopharmacology"},{"key":"3722_CR105","unstructured":"Gilgamesh Pharmaceuticals. (2025). Gilgamesh Pharma Announces Positive Topline Phase 2a Results for Blixeprodil (GM-1020) in Major Depressive Disorder. Retrieved from https:\/\/www.biospace.com\/press-releases\/gilgamesh-pharma-announces-positive-topline-phase-2a-results-for-blixeprodil-gm-1020-in-major-depressive-disorder."},{"key":"3722_CR106","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/j.brs.2020.01.005","volume":"13","author":"JC Brown","year":"2020","unstructured":"Brown JC, DeVries WH, Korte JE, Sahlem GL, Bonilha L, Short EB, et al. NMDA receptor partial agonist, d-cycloserine, enhances 10 Hz rTMS-induced motor plasticity, suggesting long-term potentiation (LTP) as underlying mechanism. Brain Stimul. 2020;13:530\u20132. https:\/\/doi.org\/10.1016\/j.brs.2020.01.005.","journal-title":"Brain Stimul"},{"key":"3722_CR107","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1016\/j.neurom.2021.09.003","volume":"25","author":"JC Brown","year":"2022","unstructured":"Brown JC, Higgins ES, George MS. Synaptic plasticity 101: the story of the AMPA receptor for the brain stimulation practitioner. Neuromodulation. 2022;25:1289\u201398. https:\/\/doi.org\/10.1016\/j.neurom.2021.09.003.","journal-title":"Neuromodulation"},{"key":"3722_CR108","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.jad.2025.02.062","volume":"377","author":"MM DeMayo","year":"2025","unstructured":"DeMayo MM, Watson M, Harris AD, McGirr A. Serum levels of D-cycloserine predict antidepressant effects in pharmacologically enhanced intermittent theta-burst stimulation. J Affect Disord. 2025;377:60\u201367. https:\/\/doi.org\/10.1016\/j.jad.2025.02.062.","journal-title":"J Affect Disord"},{"key":"3722_CR109","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1001\/jamapsychiatry.2022.3255","volume":"79","author":"J Cole","year":"2022","unstructured":"Cole J, Sohn MN, Harris AD, Bray SL, Patten SB, McGirr A. Efficacy of adjunctive D-Cycloserine to intermittent theta-burst stimulation for major depressive disorder: a randomized clinical trial. JAMA Psychiatry. 2022;79:1153\u201361. https:\/\/doi.org\/10.1001\/jamapsychiatry.2022.3255. Erratum in: JAMA Psychiatry. 2022 Dec 1;79(12):1241. 10.1001\/jamapsychiatry.2022.4059.","journal-title":"JAMA Psychiatry"},{"key":"3722_CR110","doi-asserted-by":"publisher","unstructured":"Cloutier A, Sullivan S, Kumar S, Brown J Marked reduction in suicidality and depression in a transcranial magnetic stimulation non-responder after augmenting with a standard available D-cycloserine dose. Transcranial Magn. Stimul. 2025, 5, https:\/\/doi.org\/10.1016\/j.transm.2025.100185.","DOI":"10.1016\/j.transm.2025.100185"},{"key":"3722_CR111","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1017\/S0033291713000512","volume":"44","author":"MT Berlim","year":"2014","unstructured":"Berlim MT, van den Eynde F, Tovar-Perdomo S, Daskalakis ZJ. Response, remission and drop-out rates following high-frequency repetitive transcranial magnetic stimulation (rTMS) for treating major depression: a systematic review and meta-analysis of randomized, double-blind and sham-controlled trials. Psychol Med. 2014;44:225\u201339. https:\/\/doi.org\/10.1017\/S0033291713000512.","journal-title":"Psychol Med"},{"key":"3722_CR112","doi-asserted-by":"publisher","first-page":"S835","DOI":"10.1192\/j.eurpsy.2023.1768","volume":"66","author":"JD Vieira de Andrade","year":"2023","unstructured":"Vieira de Andrade JD, Brito MJ. When the SAINT goes marching in \u2013 A novel transcranial magnetic stimulation protocol shows miraculous promise. Eur Psychiatry. 2023;66:S835 https:\/\/doi.org\/10.1192\/j.eurpsy.2023.1768.","journal-title":"Eur Psychiatry"},{"key":"3722_CR113","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.1038\/s41380-024-02468-x","volume":"29","author":"GI Papakostas","year":"2024","unstructured":"Papakostas GI, Trivedi MH, Shelton RC, Iosifescu DV, Thase ME, Jha MK, et al. Comparative effectiveness research trial for antidepressant incomplete and non-responders with treatment resistant depression (ASCERTAIN-TRD) a randomized clinical trial. Mol Psychiatry. 2024;29:2287\u201395. https:\/\/doi.org\/10.1038\/s41380-024-02468-x.","journal-title":"Mol Psychiatry"},{"key":"3722_CR114","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1176\/appi.ajp.2019.19070720","volume":"177","author":"EJ Cole","year":"2020","unstructured":"Cole EJ, Stimpson KH, Bentzley BS, Gulser M, Cherian K, Tischler C, et al. Stanford accelerated intelligent neuromodulation therapy for treatment-resistant depression. Am J Psychiatry. 2020;177:716\u201326. https:\/\/doi.org\/10.1176\/appi.ajp.2019.19070720.","journal-title":"Am J Psychiatry"},{"key":"3722_CR115","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1176\/appi.ajp.2021.20101429","volume":"179","author":"EJ Cole","year":"2022","unstructured":"Cole EJ, Phillips AL, Bentzley BS, Stimpson KH, Nejad R, Barmak F, et al. Stanford neuromodulation therapy (SNT): a double-blind randomized controlled trial. Am J Psychiatry. 2022;179:132\u201341. https:\/\/doi.org\/10.1176\/appi.ajp.2021.20101429.","journal-title":"Am J Psychiatry"},{"key":"3722_CR116","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1002\/wps.70032","volume":"25","author":"IH Kratter","year":"2026","unstructured":"Kratter IH, Austelle CW, Lissemore JI, Wada M, Geoly A, Chaiken A, et al. Stanford neuromodulation therapy for treatment-resistant depression: a randomized controlled trial confirming efficacy, and an EEG study providing insight into mechanism of action and a potentially predictive biomarker of efficacy. World Psychiatry. 2026;25:105\u201316. https:\/\/doi.org\/10.1002\/wps.70032.","journal-title":"World Psychiatry"},{"key":"3722_CR117","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1001\/jamapsychiatry.2024.1787","volume":"81","author":"YI Sheline","year":"2024","unstructured":"Sheline YI, Makhoul W, Batzdorf AS, Nitchie FJ, Lynch KG, Cash R, et al. Accelerated intermittent theta-burst stimulation and treatment-refractory bipolar depression: a randomized clinical trial. JAMA Psychiatry. 2024;81:936\u201341. https:\/\/doi.org\/10.1001\/jamapsychiatry.2024.1787. Erratum in: JAMA Psychiatry. 2024 Sep 1;81(9):948. doi: 10.1001\/jamapsychiatry.2024.2327. PMID: 38985492; PMCID: PMC11238064.","journal-title":"JAMA Psychiatry"},{"key":"3722_CR118","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1016\/j.brs.2021.07.005","volume":"14","author":"L Zwienenberg","year":"2021","unstructured":"Zwienenberg L, Iseger TA, Dijkstra E, Rouwhorst R, van Dijk H, Sack AT, et al. Neuro-cardiac guided rTMS as a stratifying method between the \u20185cm\u2019 and \u2018BeamF3\u2019 stimulation clusters. Brain Stimul. 2021;14:1070\u20132. https:\/\/doi.org\/10.1016\/j.brs.2021.07.005.","journal-title":"Brain Stimul"},{"key":"3722_CR119","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/j.bpsgos.2023.01.003","volume":"3","author":"E Dijkstra","year":"2023","unstructured":"Dijkstra E, van Dijk H, Vila-Rodriguez F, Zwienenberg L, Rouwhorst R, Coetzee JP, et al. Transcranial magnetic stimulation-induced heart-brain coupling: implications for site selection and frontal thresholding-preliminary findings. Biol Psychiatry Glob Open Sci. 2023;3:939\u201347. https:\/\/doi.org\/10.1016\/j.bpsgos.2023.01.003.","journal-title":"Biol Psychiatry Glob Open Sci"},{"key":"3722_CR120","doi-asserted-by":"publisher","DOI":"10.1111\/psyp.14631","volume":"61","author":"Y Jiao","year":"2024","unstructured":"Jiao Y, Cheng C, Jia M, Chu Z, Song X, Zhang M, et al. Neuro-cardiac-guided transcranial magnetic stimulation: Unveiling the modulatory effects of low-frequency and high-frequency stimulation on heart rate. Psychophysiology. 2024;61:e14631 https:\/\/doi.org\/10.1111\/psyp.14631.","journal-title":"Psychophysiology"},{"key":"3722_CR121","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1038\/s41386-018-0009-9","volume":"43","author":"PB Fitzgerald","year":"2018","unstructured":"Fitzgerald PB, Hoy KE, Elliot D, Susan McQueen RN, Wambeek LE, Daskalakis ZJ. Accelerated repetitive transcranial magnetic stimulation in the treatment of depression. Neuropsychopharmacology. 2018;43:1565\u201372. https:\/\/doi.org\/10.1038\/s41386-018-0009-9.","journal-title":"Neuropsychopharmacology"},{"key":"3722_CR122","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.jad.2016.04.015","volume":"200","author":"R Duprat","year":"2016","unstructured":"Duprat R, Desmyter S, de Rudi R, van Heeringen K, Van den Abbeele D, Tandt H, et al. Accelerated intermittent theta burst stimulation treatment in medication-resistant major depression: A fast road to remission? J Affect Disord. 2016;200:6\u201314. https:\/\/doi.org\/10.1016\/j.jad.2016.04.015.","journal-title":"J Affect Disord"},{"key":"3722_CR123","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1002\/da.20731","volume":"27","author":"PE Holtzheimer 3rd","year":"2010","unstructured":"Holtzheimer PE 3rd, McDonald WM, Mufti M, Kelley ME, Quinn S, Corso G, et al. Accelerated repetitive transcranial magnetic stimulation for treatment-resistant depression. Depress Anxiety. 2010;27:960\u20133. https:\/\/doi.org\/10.1002\/da.20731.","journal-title":"Depress Anxiety"},{"key":"3722_CR124","doi-asserted-by":"crossref","unstructured":"Vaughn D, Marino B, Engelbertson A, Dojnov A, Johnson L, Stine M et al. (2025a). Single-day TMS regimens with pharmacological augmentation of plasticity: Five cases. Transcranial Magnetic Stimulation, 4(100176), Article 100176.","DOI":"10.1016\/j.transm.2025.100176"},{"key":"3722_CR125","doi-asserted-by":"publisher","DOI":"10.1016\/j.transm.2025.100200","volume":"ume 5","author":"D Vaughn","year":"2025","unstructured":"Vaughn D, Marino B, Engelbertson A, Dojnov A, Johnson L, Stine M, et al. Real-world effectiveness of a single-day regimen for transcranial magnetic stimulation using Optimized, Neuroplasticity-Enhanced techniques in Depression (ONE-D): An open-label case series. Transcranial Magnetic Stimulation. 2025b;ume 5:100200 https:\/\/doi.org\/10.1016\/j.transm.2025.100200. ISSN 3050-5291.","journal-title":"Transcranial Magnetic Stimulation"},{"key":"3722_CR126","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1176\/appi.ajp.2019.19090915","volume":"177","author":"SH Siddiqi","year":"2020","unstructured":"Siddiqi SH, Taylor SF, Cooke D, Pascual-Leone A, George MS, Fox MD. Distinct symptom-specific treatment targets for circuit-based neuromodulation. Am J Psychiatry. 2020;177:435\u201346. https:\/\/doi.org\/10.1176\/appi.ajp.2019.19090915.","journal-title":"Am J Psychiatry"},{"key":"3722_CR127","doi-asserted-by":"publisher","first-page":"S32","DOI":"10.1016\/j.biopsych.2024.02.084","volume":"95","author":"J Taylor","year":"2024","unstructured":"Taylor J, Li J, Lin C, Jones E, Santos E, Fox M, et al. Symptom specific TMS targets for depression and anxiety: a randomized, controlled trial. Biol Psychiatry. 2024;95:S32\u2013S33. https:\/\/doi.org\/10.1016\/j.biopsych.2024.02.084.","journal-title":"Biol Psychiatry"},{"key":"3722_CR128","unstructured":"Alto Neuroscience. (2025, February 12). Alto Neuroscience announces favorable outcome from interim analysis of ALTO-300 Phase 2b Major Depressive Disorder trial [Press release]. Business Wire. https:\/\/investors.altoneuroscience.com\/news\/news-details\/2025\/Alto-Neuroscience-Announces-Favorable-Outcome-from-Interim-Analysis-of-ALTO-300-Phase-2b-Major-Depressive-Disorder-Trial\/default.aspx."},{"key":"3722_CR129","unstructured":"Denovo Biopharma. (2024, April 9). Denovo Biopharma announces a major breakthrough in treatment-resistant depression with precision medicine. Business Wire. https:\/\/www.businesswire.com\/news\/home\/20240409550498\/en\/Denovo-Biopharma-Announces-a-Major-Breakthrough-in-Treatment%E2%80%91Resistant-Depression-with-Precision-Medicine."},{"key":"3722_CR130","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2025.116506","volume":"348","author":"C Guidetti","year":"2025","unstructured":"Guidetti C, Fava M, Manfredi PL, Pappagallo M, Gomeni R. A novel artificial intelligence-based methodology to predict non-specific response to treatment. Psychiatry Res. 2025;348:116506 https:\/\/doi.org\/10.1016\/j.psychres.2025.116506.","journal-title":"Psychiatry Res"},{"key":"3722_CR131","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1038\/s41746-025-02143-7","volume":"8","author":"J Geraci","year":"2025","unstructured":"Geraci J, Qorri B, Tsay M, Cumbaa C, Leonczyk P, Alphs L, et al. Explainable AI-driven precision clinical trial enrichment: demonstration of the NetraAI platform with a phase II depression trial. NPJ Digit Med. 2025;8:749 https:\/\/doi.org\/10.1038\/s41746-025-02143-7.","journal-title":"NPJ Digit Med"}],"container-title":["Molecular Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41380-026-03722-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41380-026-03722-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41380-026-03722-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T20:57:45Z","timestamp":1792011465000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41380-026-03722-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,25]]},"references-count":131,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["3722"],"URL":"https:\/\/doi.org\/10.1038\/s41380-026-03722-0","relation":{},"ISSN":["1359-4184","1476-5578"],"issn-type":[{"value":"1359-4184","type":"print"},{"value":"1476-5578","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,25]]},"assertion":[{"value":"21 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"CG has served as a consultant for or has financial interests in Bristol Myers Squibb, Levomecor, MGGM, and NeuroArbor Therapeutics. GIP has served as a consultant for Abbott, Alkermes, AstraZeneca, Arrivo Bioventures\u2013Sirtsei Pharmaceuticals, Avanir, Boehringer Ingelheim, BrainsWay, Bristol Myers Squibb, Cephalon, Dey Pharma, Eli Lilly, GlaxoSmithKline, Evotec, Lundbeck, Inflabloc Pharmaceuticals, Jazz Pharmaceuticals, Methylation Sciences, Neurocentria, Novartis, Otsuka, Pamlab, Pfizer, Pierre Fabre Laboratories, Ridge Diagnostics, Shire Pharmaceuticals, Takeda, Theracos, and Wyeth; he has also served as a consultant on behalf of Massachusetts General Hospital for Acadia Pharmaceuticals, Alfasigma USA, Almatica, Axsome Therapeutics, Boston Pharmaceuticals, Cala Health, Eleusis Health Solutions, Genentech, Genomind, Janssen Global Services, Johnson & Johnson, Merck, Monopteros Therapeutics, Mylan, One-carbon Therapeutics, Osmotica Pharmaceuticals, Praxis Precision Medicines, Sage Therapeutics, Sunovion, and Taisho; he has received honoraria for lectures or consultancy from Abbott, AbbVie, Acadia Pharmaceuticals, Alfasigma USA, Alkermes, Asofarma Centroam\u00e9rica Y Caribe, AstraZeneca, Avanir, Boehringer Ingelheim, BrainsWay, Bristol Myers Squibb, Cephalon, Dey Pharma, Eli Lilly, Evotec AG, Forest Pharmaceuticals, GlaxoSmithKline, Grunbiotics, Hypera SA, Inflabloc Pharmaceuticals, Jazz Pharmaceuticals, Lundbeck, Medichem Pharmaceuticals, Meiji Seika Pharma, Novartis, Otsuka, Pamlab, Pfizer, Pharma Trade SAS, Pierre Fabre Laboratories, Ridge Diagnostics, Shire Pharmaceuticals, Sunovion, Takeda, Theracos, Titan Pharmaceuticals, and Wyeth; he has received research support (paid to hospital) from Alfasigma, AstraZeneca, Beckley Psytech, Bristol Myers Squibb, Cala Health, Forest Pharmaceuticals, Johnson & Johnson, Mylan, Neuralstem, NIMH, Pamlab, PCORI, Pfizer, Ridge Diagnostics, Sunovion, Tal Medical, and Theracos; he has served on speakers bureaus for Bristol Myers Squibb and Pfizer. MF has received research support from Acadia Pharmaceuticals, Aditum Bio Management Company, Alkermes, Allergan, Altimate Health, Alto Neuroscience, Ancora Bio, Angelini, Aptinyx, Arbor Pharmaceuticals, Avanir, Axsome, Benckiser Pharmaceuticals, BioClinica, Biogen, Biohaven, BioShin Limited, Cambridge Science, Centrexion Therapeutics, Cerecor, Cybin IRL, Eliem Therapeutics, Gate Neurosciences, Genomind, Gentelon, Happify, Johnson & Johnson, Lundbeck, Marinus Pharmaceuticals, Methylation Sciences, Millennium Pharmaceuticals, Minerva Neurosciences, Neuralstem, Neurocrine Biosciences, NeuroRx, NIDA, NIMH, Novaremed, Novartis, Otsuka, Pfizer, PCORI, Premier Research International, Praxis Precision Medicines, Protagenic Therapeutics, Relmada Therapeutics, Reckitt, Shenox Pharmaceuticals, the Stanley Medical Research Institute, Taisho, Takeda, University of Michigan, Vistagen, WinSanTor, and Xenon Pharmaceuticals; he has served as a consultant for Sensorium Therapeutics; he has equity holdings in Compellis Pharmaceuticals, Neuromity Therapeutics, Psy Therapeutics, and Sensorium Therapeutics; he holds patents for sequential parallel comparison design (licensed by Massachusetts General Hospital to Pharmaceutical Product Development) (US_7840419, US_7647235, US_7983936, US_8145504, US_8145505), a patent application for a combination of ketamine plus scopolamine in major depressive disorder (licensed by MGH to Biohaven), and patents for pharmacogenomics of depression treatment with folate (US_9546401, US_9540691); he is a copyright holder for the MGH Cognitive and Physical Functioning Questionnaire, the Sexual Functioning Inventory, the Antidepressant Treatment Response Questionnaire, the Discontinuation-Emergent Signs and Symptoms Scale, the Symptoms of Depression Questionnaire, and SAFER; and he receives royalties from Belvoir, Lippincott Williams & Wilkins, Wolters Kluwer, and World Scientific Publishing Co.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}